论文部分内容阅读
目的观察胰岛素联合罗格列酮治疗早期糖尿病肾病的疗效。方法2008年3月-2009年2月,将61例符合早期糖尿病肾病的患者随机分为治疗组和对照组。对照组30例予糖尿病基础治疗,治疗组31例加用胰岛素和罗格列酮。治疗观察6个月。比较治疗前后两组空腹血糖(FBG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(Homa-IR)、尿白蛋白排泄率(UAER)等变化情况。结果治疗组在治疗后FBG、HbA1c、Homa-IR、UAER均较治疗前明显改善,差异有统计学意义(P<0.05),且FBG、HbA1c、UAER的下降较对照组明显(P<0.05)。结论胰岛素联合罗格列酮可有效调控早期糖尿病肾病患者的血糖,改善胰岛素抵抗,减少尿蛋白排泄,保护肾功能。
Objective To observe the efficacy of insulin combined with rosiglitazone in the treatment of early diabetic nephropathy. Methods From March 2008 to February 2009, 61 patients with early diabetic nephropathy were randomly divided into treatment group and control group. Control group, 30 cases of basic treatment of diabetes, the treatment group, 31 cases plus insulin and rosiglitazone. Treatment observed for 6 months. The changes of fasting blood glucose (FBG), HbA1c, Homa-IR and urinary albumin excretion rate (UAER) were compared before and after treatment. Results The FBG, HbA1c, Homa-IR and UAER of the treatment group were significantly improved after treatment (P <0.05), and the decrease of FBG, HbA1c and UAER was significantly (P <0.05) . Conclusion Insulin combined with rosiglitazone can effectively regulate the blood sugar of patients with early diabetic nephropathy, improve insulin resistance, reduce urinary protein excretion and protect renal function.